Cyclosporine A does not prevent second-eye involvement in Leber’s hereditary optic neuropathy

Table 1 Clinical data of five LHON patients at baseline and exit examinations during the cyclosporine trial

Patient	Age	Gender	mtDNA mutation	Heteroplasmy level (%)	Baseline Visual function First eye		Baseline visual function Second eye		Time between initial visual loss and beginning of treatment (weeks)	Time between beginning of treatment and second eye visual loss (weeks)	Time between involvement of the two eyes (weeks)	Exit Visual Function First Eye		Exit Visual Function Second Eye
Patient	Age	Gender	mtDNA mutation	Heteroplasmy level (%)	Visual acuity (logMar) [Snellen]	Visual field (MD)	Visual acuity (logMar) [Snellen]	Visual field (MD)			Time between involvement of the two eyes (weeks)	Visual acuity (logMar) [Snellen]	Visual field (MD)	Visual acuity (logMAr) [Snellen]	Visual field (MD)
1	42	F	11778	98.17	0.8 [20/125]	−1.24	0 [20/20]	0.65	16	15	31	2.1 [HM]	−32.55	2.1 [HM]	−32.08
2	30	M	11778	100	0.5 [20/63]	−2.89	0 [20/20]	−1.88	17	11	28	1.6 [20/800]	−22.85	1.1 [20/250]	−12.41
3	26	M	11778	98	1.1 [20/250]	−7.81	0 [20/20]	−2.17	9	65	74	2.1 [HM]	−33.99	2.1 [HM]	−29.49
4	19	M	14484	100	0.7 [20/100]	−4.97	−0.1 [20/16]	−1.45	6	12	18	0.9 [20/160]	−25.77	1 [20/200]	−29.28
5	19	M	11778	97	1.1 [20/250]	−8.86	−0.1 [20/16]	−2.11	9	18	27	2.40 [HM]	−34.62	1.2 [20/320]	−18.94
Mean	27.2	–	–	98.63	0.84 [20/125]	−5.15-	0 [20/20]	−1.392	11.4	24.2	35.6	1.82 [CF]	−29.96	1.50 [20/500]	−24.44
Median	26	–	–	98.17	0.8 [20/125]	−4.97	0 [20/20]	−1.88	9	15	28	2.1 [HM]	−31.25	1.2 [20/300]	−26.86

ISSN: 1750-1172